Medical Compositions for Intravesical Treatment of Bladder Cancer

Abstract

Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.

1 - 4 . (canceled)  
   
   
       5 . A medical composition for the intravesical treatment of bladder cancer comprising: 
 a) 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09);    b) propylene glycol;    c) water; and    c) sufficient sodium bicarbonate to maintain a pH between 9.0 and 9.5.    
   
   
       6 . The medical composition according to  claim 5  further comprising sodium edetate.  
   
   
       7 . The medical composition according to  claim 5  wherein said E09 concentration is between 0.0125 mg/mL to 0.4 mg/mL.  
   
   
       8 . The medicament according to  claim 5  wherein said propylene glycol is present in a ration of 60 parts to 40 parts of water (v/v).  
   
   
       9 . The medicament according to  claim 5  wherein said sodium bicarbonate is present at a concentration of 2% (w/v).  
   
   
       10 . The medical composition according to  claim 6  wherein said sodium edentate is present in a concentration pf 0.02% (w/v).  
   
   
       11 . The medical composition according to  claim 5  comprising an 8 mg unit dose of E09.  
   
   
       12 . The medical composition according to claims  5  and  6  wherein said, propylene glycol, water, sodium bicarbonate and sodium edentate are present in the ratio of 60/40/2/0.02% v/v/w/w and said E09 is present in a concentration of from 0.0125 mg/mL to 0.4 mg/mL  
   
   
       13 . The medical composition according to  claim 11  where in said E09 is present at 0.2 mg/mL.  
   
   
       14 . The medical composition according to  claim 11  where in said E09 is present at 0.4 mg/mL.